Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
PremiumPress ReleasesAlmirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
6M ago
Eloxx Pharmaceuticals (ELOX) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Eloxx Pharmaceuticals (ELOX) Q4 Earnings Cheat Sheet
7M ago
Eloxx Pharmaceuticals files to sell 778,646 shares of common stock for holders
Premium
The Fly
Eloxx Pharmaceuticals files to sell 778,646 shares of common stock for holders
8M ago
Eloxx Pharmaceuticals reports results of patient biopsy assessment by NIPOKA
PremiumThe FlyEloxx Pharmaceuticals reports results of patient biopsy assessment by NIPOKA
12M ago
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
Premium
Press Releases
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
12M ago
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Premium
Press Releases
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
1y ago
Eloxx Pharma (NASDAQ:ELOX) Rises on Promising Phase 2 Data in Alport Syndrome
PremiumMarket NewsEloxx Pharma (NASDAQ:ELOX) Rises on Promising Phase 2 Data in Alport Syndrome
1y ago
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
Premium
Press Releases
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
1y ago
Eloxx Pharmaceuticals reports Q2 EPS ($1.96) vs ($4.90) last year
Premium
The Fly
Eloxx Pharmaceuticals reports Q2 EPS ($1.96) vs ($4.90) last year
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100